New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT05941507

Recruiting now Disease control Sponsor: LigaChem Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called LCB84, which targets a protein (TROP2) found on many cancer cells and delivers a toxic payload directly to them. It is being tested alone and together with an immunotherapy drug (anti-PD-1) in 300 people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drugs can shrink tumors or slow cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LCB84 (a drug that targets TROP2 on cancer cells and delivers a chemotherapy-like agent) and an anti-PD-1 antibody (a type of immunotherapy)
What this could lead to: If successful, this could provide a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2), so the safety and effectiveness are not yet proven. Side effects from the drug combination could be significant, and the treatment may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anus neoplasm breast neoplasm endometrium neoplasm gastric neoplasm glioblastoma Head and Neck Neoplasms lung neoplasm neoplasm ovarian cancer pancreatic neoplasm salivary gland cancer Squamous Cell Carcinoma of Head and Neck Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Cedars Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75230, United States
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Tennessee Oncology
NOT_YET_RECRUITING

Nashville, Tennessee, 37203, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Texas Southwestern Medical Center
NOT_YET_RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.